Discover 1 curated intelligence briefings related to this specific topic.
From AI-designed CRISPR enzymes to de novo antibodies, the pharmaceutical industry is moving away from the 'lucky guess' and toward a physics-based engineering discipline that treats proteins as programmable software.
